These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34796851)

  • 1. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
    de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
    Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome.
    Ture HY; Kim NR; Nam EJ
    Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.
    Seror R; Meiners P; Baron G; Bootsma H; Bowman SJ; Vitali C; Gottenberg JE; Theander E; Tzioufas A; De Vita S; Ramos-Casals M; Dörner T; Quartuccio L; Ravaud P; Mariette X;
    Ann Rheum Dis; 2016 Nov; 75(11):1945-1950. PubMed ID: 27150113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure.
    Arends S; de Wolff L; van Nimwegen JF; Verstappen GMPJ; Vehof J; Bombardieri M; Bowman SJ; Pontarini E; Baer AN; Nys M; Gottenberg JE; Felten R; Ray N; Vissink A; Kroese FGM; Bootsma H
    Lancet Rheumatol; 2021 Aug; 3(8):e553-e562. PubMed ID: 38287621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
    Wang ZZ; Zheng QS; Liu HX; Li LJ
    Front Immunol; 2021; 12():783246. PubMed ID: 34868062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
    Front Immunol; 2019; 10():1527. PubMed ID: 31354708
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.
    Brito-Zerón P; Acar-Denizli N; Ng WF; Horváth IF; Rasmussen A; Seror R; Li X; Baldini C; Gottenberg JE; Danda D; Quartuccio L; Priori R; Hernandez-Molina G; Armagan B; Kruize AA; Kwok SK; Kvarnstrom M; Praprotnik S; Sene D; Gerli R; Solans R; Rischmueller M; Mandl T; Suzuki Y; Isenberg D; Valim V; Wiland P; Nordmark G; Fraile G; Bootsma H; Nakamura H; Giacomelli R; Devauchelle-Pensec V; Hofauer B; Bombardieri M; Trevisani VFM; Hammenfors D; Pasoto SG; Retamozo S; Gheita TA; Atzeni F; Morel J; Vollenweider C; Zeher M; Sivils K; Xu B; Bombardieri S; Sandhya P; De Vita S; Minniti A; Sánchez-Guerrero J; Kilic L; van der Heijden E; Park SH; Wahren-Herlenius M; Mariette X; Ramos-Casals M;
    Rheumatology (Oxford); 2020 Sep; 59(9):2350-2359. PubMed ID: 31873754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.
    James K; Chipeta C; Parker A; Harding S; Cockell SJ; Gillespie CS; Hallinan J; Barone F; Bowman SJ; Ng WF; Fisher BA;
    Rheumatology (Oxford); 2018 Jul; 57(7):1222-1227. PubMed ID: 29608774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
    Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
    Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
    Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
    Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
    Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
    Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity.
    Bodewes ILA; Al-Ali S; van Helden-Meeuwsen CG; Maria NI; Tarn J; Lendrem DW; Schreurs MWJ; Steenwijk EC; van Daele PLA; Both T; Bowman SJ; Griffiths B; Ng WF; ; Versnel MA
    Rheumatology (Oxford); 2018 May; 57(5):921-930. PubMed ID: 29474655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.